Company news
News Center
News center
202506-06
Welcome to Shanghai CPHI Exhibition!
CPHI China 2025 – Shanghai
Lunarsun warmly welcomes you to the World Pharmaceutical Ingredients Exhibition!
Date: June 24–26, 2025
Address: Shanghai New International Expo Centre (SNIEC), Pudong
Booth No.: W4 Q02
We sincerely invite both new and existing partners to visit us for business discussions!
202412-26
Our new website has launched on December 26, 2024.
Our website have a revision and upgrade. The new one is launched on December 26,2024.
202409-14
Congratulations to Lunarsun Pharmaceuticals on the National Medical Products Administration approval of Tigecycline for Injection!
Lunarsun Pharma's Tigecycline for Injection has officially been approved for marketing.
Approval Number: H20244853
We welcome your inquiries and cooperation!
202408-05
Congratulations to Lunarsum Pharmaceuticals on the National Medical Products Administration Approval of Famotidine Injection!
Lunarsum Pharma's Famotidine Injection has been officially approved for marketing.
Approval Number: H20244490
We welcome your inquiries and cooperation!
202401-18
Congratulations to Lunarsun on the Successful Status Upgrade of Mirabegron to “Active”!
Beijing Lunarsun Pharma is proud to announce that the imported API Mirabegron was successfully approved for turning into “Active ”on January 18, 2024.
Registration Number: Y20210000398
We warmly invite pharmaceutical manufacturers to reach out for collaboration opportunities.
202302-24
Welcome to Qingdao API Exhibition!
Qingdao API Exhibition
Time: December 14, 2023
Location: Qingdao
Booth number: N4 H12
Welcome new and old customers to visit and negotiate!
202203-29
Congratulations to Lunarsun Pharmaceuticals on the public announcement of their new active pharmaceutical ingredients, oseltamivir and everalen!
In March 2022, congratulations to Lairuisen Pharmaceuticals on successfully passing the evaluation and activating the registration status "A" for the import declaration of raw materials oseltamivir and efaviren. Welcome to cooperate.
